CCLD vs DOCS

For growth investors, Doximity, Inc.

(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus 8. 7% for CareCloud, Inc. (CCLD). Doximity, Inc. (DOCS) offers the better valuation at 23. 5x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate CareCloud, Inc. (CCLD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Doximity, Inc.

(DOCS) is the cheapest at 23. 5x versus CareCloud, Inc. at 24. 9x. On forward P/E, CareCloud, Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Doximity, Inc.

(DOCS) delivered a total return of -50. 9%, compared to -69. 5% for CareCloud, Inc. (CCLD). Over 10 years, the gap is even starker: CCLD returned +155. 4% versus DOCS's -50. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Doximity, Inc.

(DOCS) is the lower-risk stock at 1. 03β versus CareCloud, Inc. 's 1. 15β — meaning CCLD is approximately 11% more volatile than DOCS relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 7% for CareCloud, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Doximity, Inc.

(DOCS) is pulling ahead at 20. 0% versus 8. 7% for CareCloud, Inc. (CCLD). On earnings-per-share growth, the picture is similar: CareCloud, Inc. grew EPS 135. 7% year-over-year, compared to 54. 2% for Doximity, Inc.. Over a 3-year CAGR, DOCS leads at 18. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus 9. 0% for CareCloud, Inc. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus 10. 1% for CCLD. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CareCloud, Inc.

(CCLD) trades at 14. 2x forward P/E versus 16. 8x for Doximity, Inc. — 2. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DOCS: 64. 4% to $42. 79.

In this comparison, CCLD (0.

7% yield) pays a dividend. DOCS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CareCloud, Inc.

(CCLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 0. 7% yield, +155. 4% 10Y return). Both have compounded well over 10 years (CCLD: +155. 4%, DOCS: -50. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CCLD is a small-cap quality compounder stock; DOCS is a small-cap high-growth stock. CCLD pays a dividend while DOCS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.